Stockreport

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Aktis Oncology, Inc. - Common stock  (AKTS) 
NASDAQ:AMEX Investor Relations: ir.akoustis.com
PDF AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentationsData facilitate initial understanding of AKY-2519 biodistribution and p [Read more]